Home
2006 Press Archive 2005 Press Archive 2004 Press Archive 2002 Press Archive 2001 Press Archive 2000 Press Archive
				Sangamo Collaborator Receives Award for Research in Vascular Medicine RICHMOND, Calif., June 11 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that Qunsheng Dai, M.D. received the Young Investigator Award from the Society for Vascular Medicine and Biology at the Society's 14th Annual Meeting held in Chicago June 6-8, 2003. Dr. Dai is a research associate in the Division of Cardiology, Department of Medicine, Duke University Medical Center. The award was presented to Dr. Dai in recognition of his contributions to a study that demonstrated the effectiveness of using engineered zinc finger DNA binding protein transcription factors (ZFP TFs) to increase the formation of new blood vessels in ischemic tissue, a collaborative effort between Sangamo and Edwards Lifesciences Corporation (NYSE: EW). The study employed the ischemic rabbit hind limb model and demonstrated that Sangamo’s and Edwards' lead therapeutic, a ZFP TF designed to activate the endogenous vascular endothelial growth factor (VEGF) gene, is capable of increasing the formation of new blood vessels resulting in a significant increase in blood flow in the ischemic limb. Dr. Dai's work, described in an abstract titled “A Genetically Engineered Plasmid Encoding a Zinc Finger VEGF-Activating Transcription Factor Induces Angiogenesis in Rabbits with Hind-Limb Ischemia,” was conducted in the laboratory of Dr. Brian Annex, M.D., Associate Professor of Medicine and Director of the Therapeutic Angiogenesis Research Program at Duke University Medical Center. "We are very proud of Qunsheng's success," said Dr. Annex. “The Society for Vascular Medicine and Biology Annual Meeting is a conference that attracts leading scientists and clinicians in vascular medicine to discuss the latest developments in the field. The study that Dr. Dai described used a novel genetic approach to stimulate the endogenous VEGF-A gene and these pre- clinical efficacy studies are quite encouraging.” “The results of Drs. Dai and Annex's study are very encouraging and validate our program to develop ZFP TFs as a novel treatment approach for peripheral vascular diseases (PAD) and ischemic heart disease," said Tyler Martin, M.D., Sangamo’s vice president of development. "These data will form part of our submission package for an investigational new drug (IND) application for PAD. We congratulate Dr. Dai on this award and wish him continued success.” About Sangamo Sangamo BioSciences, Inc., of Richmond, CA, is focused on the research and development of novel transcription factors for the regulation of gene expression. The company’s most advanced therapeutic development program involves the use of transcription factors for the treatment of coronary artery disease and peripheral arterial disease. Other therapeutic development programs are focused on cancer and infectious diseases. Sangamo’s proprietary technology enables the engineering of transcription factors known as zinc finger DNA-binding proteins, or ZFPs. By engineering ZFPs so that they can recognize a specific gene, Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. The company is developing ZFP TFs as a fundamentally enabling technology for commercial applications in human therapeutics, pharmaceutical discovery and plant agriculture. For more information about Sangamo, visit the company’s web site at www.sangamo.com. This press release may contain forward-looking statements based on Sangamo’s current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and applications of Sangamo’s ZFP TF Therapeutic programs. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Sangamo’s ability to develop commercially viable products and technological developments by our competitors. See the company’s SEC filings, and in particular, the risk factors described in the company’s Annual Report on Form 10-K and their most recent 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release. SOURCE Sangamo BioSciences, Inc. 06/11/2003 CONTACT: Elizabeth Wolffe, Ph.D. of Sangamo BioSciences, Inc., +1-510-970-6000, ext. 271, or ewolffe@sangamo.com Web site: http://www.sangamo.com (SGMO EW) back to top
Contact Careers Site Map Legal Glossary